Edwards Lifesciences (EW) to Release Earnings on Tuesday

Edwards Lifesciences (NYSE:EW) will issue its quarterly earnings data after the market closes on Tuesday, April 23rd. Analysts expect the company to announce earnings of $1.23 per share for the quarter. Edwards Lifesciences has set its Q1 guidance at $1.15-1.25 EPS and its FY19 guidance at $5.05-5.30 EPS.Parties interested in registering for the company’s conference call can do so using this link.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.17. The business had revenue of $977.70 million for the quarter, compared to analyst estimates of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same quarter last year, the business posted $0.94 EPS. On average, analysts expect Edwards Lifesciences to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

NYSE EW opened at $177.26 on Monday. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19. The company has a market cap of $36.88 billion, a P/E ratio of 37.71, a PEG ratio of 2.31 and a beta of 0.91. Edwards Lifesciences has a 1 year low of $123.00 and a 1 year high of $197.86.

EW has been the topic of several analyst reports. Bank of America increased their price target on shares of Edwards Lifesciences from $190.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. Citigroup increased their price target on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the stock a “sell” rating in a research report on Wednesday, January 2nd. JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $175.00 to $190.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 27th. They noted that the move was a valuation call. Deutsche Bank initiated coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 2nd. They set a “hold” rating and a $164.00 price target on the stock. Finally, Morgan Stanley increased their price target on shares of Edwards Lifesciences from $180.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus price target of $182.29.

In other Edwards Lifesciences news, VP Larry L. Wood sold 6,716 shares of the firm’s stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $169.10, for a total value of $1,135,675.60. Following the sale, the vice president now owns 35,224 shares in the company, valued at $5,956,378.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of Edwards Lifesciences stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $177.75, for a total transaction of $977,625.00. Following the transaction, the vice president now owns 24,482 shares in the company, valued at approximately $4,351,675.50. The disclosure for this sale can be found here. Insiders sold 114,328 shares of company stock worth $20,121,304 in the last 90 days. Company insiders own 1.63% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/22/edwards-lifesciences-ew-to-release-earnings-on-tuesday.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Earnings History for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.